维利帕尼联合卡铂或单用卡铂加入新辅助化疗治疗三阴性乳腺癌(BrighTNess):随机III期试验
BrighTNess研究是一项随机双盲安慰剂对照III期试验,纳入634例II-III期三阴性乳腺癌患者,评估在紫杉醇序贯多柔比星+环磷酰胺的新辅助化疗中加入维利帕尼+卡铂或单用卡铂的疗效。加用卡铂毒性增加但可控,维利帕尼未显著增加毒性。
要点
- 紫杉醇+卡铂+维利帕尼组pCR率53%,显著高于紫杉醇单药组的31%。
- 卡铂增加3/4级毒性和严重不良事件,但可控,维利帕尼未显著增加毒性。
核心结论
- 在紫杉醇序贯多柔比星+环磷酰胺的新辅助化疗中加入维利帕尼和卡铂可提高三阴性乳腺癌的pCR率。
- 但维利帕尼加入卡铂和紫杉醇并未进一步提高pCR率。
- 加用卡铂毒性增加但可控,不影响后续治疗的实施,可能作为高危三阴性乳腺癌新辅助化疗的潜在组成部分。
研究设计与样本
- III期随机双盲安慰剂对照试验(BrighTNess),在15个国家145个中心开展。
- 纳入634例既往未治疗的组织学或细胞学确诊的临床II-III期三阴性乳腺癌患者,ECOG评分0或1,适合潜在根治性手术。
- 按2:1:1随机分配至紫杉醇+卡铂+维利帕尼组(316例)、紫杉醇+卡铂+维利帕尼安慰剂组(160例)或紫杉醇+卡铂安慰剂+维利帕尼安慰剂组(158例)。
- 主要终点为乳腺和淋巴结的病理完全缓解率(由中心病理学家评估),疗效分析按意向治疗人群,安全性分析包括所有接受至少一剂研究治疗的患者。
主要发现
- 接受卡铂的患者3/4级毒性和严重不良事件更常见,维利帕尼未显著增加毒性。
- 总体最常见3/4级事件为中性粒细胞减少(56%,352/628)、贫血(29%,180/628)和血小板减少(12%,75/628)。
- 最常见严重不良事件为发热性中性粒细胞减少(13%,80/628)和贫血(3%,20/628)。
关键数值与推荐
- 3/4级中性粒细胞减少发生率56%(352/628),贫血29%(180/628),血小板减少12%(75/628)。
- 严重不良事件发热性中性粒细胞减少13%(80/628),贫血3%(20/628)。
临床怎么用
- 对于高危三阴性乳腺癌患者,可考虑在新辅助化疗中加入卡铂,以提高病理完全缓解率。
- 加用卡铂时需监测血液学毒性,尤其是中性粒细胞减少和贫血,但毒性总体可控。
- 不推荐在卡铂和紫杉醇基础上常规加用维利帕尼,因未显示额外获益。
局限性
- 本文报告的是正在进行试验的首次结果,数据截止日期为2016年12月8日。
- 未报告长期生存结局(如无事件生存期和总生存期)。
- 研究未设紫杉醇+维利帕尼组,无法单独评估维利帕尼的贡献。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Although several randomised trials in patients with triple-negative breast cancer have shown that the addition of carboplatin, with or without poly(ADP-ribose) polymerase (PARP) inhibitors, to neoadjuvant chemotherapy increases the likelihood of achieving a pathological complete response, the use of these therapies in this setting has remained controversial. The BrighTNess trial was designed to assess the addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer. METHODS: We did a phase 3, randomised, double-blind, placebo-controlled trial (BrighTNess) across 145 sites in 15 countries. Patients aged 18 years and older with previously untreated histologically or cytologically confirmed clinical stage II-III triple-negative breast cancer, who were candidates for potentially curative surgery and had an Eastern Cooperative Oncology Group performance status of 0 or 1, were randomly assigned (2:1:1) by an interactive response technology system via permuted blocks (block size of four) within strata to receive one of three segment 1 regimens: paclitaxel (80 mg/m2 intravenously weekly for 12 doses) plus carboplatin (area under the curve 6 mg/mL per min, intravenously every 3 weeks, for four cycles) plus veliparib (50 mg orally, twice a day); paclitaxel plus carboplatin plus veliparib placebo (twice a day); or paclitaxel plus carboplatin placebo (every 3 weeks for four cycles) plus veliparib placebo. Following segment 1, all patients were assigned to segment 2 in which they received doxorubicin and cyclophosphamide every 2-3 weeks for four cycles. Randomisation for segment 1 was stratified by germline BRCA mutation status, nodal stage, and planned schedule of doxorubicin and cyclophosphamide administration. The primary endpoint was pathological complete response in breast and lymph nodes as determined by site pathologists following completion of neoadjuvant therapy. Efficacy analyses were done by intention to treat and safety analyses included all patients who received at least one dose of study treatment. These are the first results of an ongoing clinical trial; the data cutoff for the analyses presented was Dec 8, 2016. This study is registered with ClinicalTrials.gov, number NCT02032277. FINDINGS: Between April 4, 2014, and March 18, 2016, 634 patients were randomly assigned: 316 to paclitaxel plus carboplatin plus veliparib, 160 to paclitaxel plus carboplatin, and 158 to paclitaxel alone. The proportion of patients who achieved a pathological complete response was higher in the paclitaxel, carboplatin, and veliparib group than in patients receiving paclitaxel alone (168 [53%] of 316 patients vs 49 [31%] of 158, p<0·0001), but not compared with patients receiving paclitaxel plus carboplatin (92 [58%] of 160 patients, p=0·36). Grade 3 or 4 toxicities, and serious adverse events were more common in patients receiving carboplatin, whereas veliparib did not substantially increase toxicity. The most common grade 3 or 4 events overall were neutropenia (352 [56%] of 628 patients), anaemia (180 [29%]), and thrombocytopenia (75 [12%]) through complete treatment, and febrile neutropenia (88 [15%] of 601 patients) during segment 2. The most common serious adverse events were febrile neutropenia (80 [13%] of 628 patients) and anaemia (20 [3%]). INTERPRETATION: Although the addition of veliparib and carboplatin to paclitaxel followed by doxorubicin and cyclophosphamide improved the proportion of patients with triple-negative breast cancer who achieved a pathological complete response, the addition of veliparib to carboplatin and paclitaxel did not. Increased toxicities with the addition of carboplatin (with or without veliparib) to paclitaxel were manageable and did not substantially affect treatment delivery of paclitaxel followed by doxorubicin and cyclophosphamide. Given the consistent results with previous studies, the addition of carboplatin appears to have a favourable risk to benefit profile and might be considered as a potential component of neoadjuvant chemotherapy for patients with high-risk, triple-negative breast cancer. FUNDING: AbbVie.
引用
- Loibl S, O'Shaughnessy J, Untch M, et al. Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial. Lancet Oncol. 2018. PMID: 29501363. doi:10.1016/S1470-2045(18)30111-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。